Summit Therapeutics's total assets for Q4 2025 were £751.18M, an increase of 187.01% from the previous quarter. SMMT total liabilities were £92.32M for the fiscal quarter, a 32.90% a decrease from the previous quarter. See a summary of the company’s assets, liabilities, and equity.